公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2018 | Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan | Wang, CK; MING-CHIH HO ; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN ; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; PO-HUANG LEE ; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Lin S.-M.; GUAN-TARN HUANG ; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; PO-CHIN LIANG ; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; ANN-LII CHENG ; CHIUN HSU ; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; CHIA-HSIEN CHENG ; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; YEN-HSUAN NI ; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group; Surveillance group; Diagnosis group; Staging group; Surgery group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group | Journal of the Formosan Medical Association = Taiwan yi zhi | 90 | 87 | |
2013 | Management of gastric cancer in Asia: Resource-stratified guidelines | Shen L.; Shan Y.-S.; Hu H.-M.; Price T.J.; Sirohi B.; KUN-HUEI YEH ; Yang Y.-H.; Sano T.; Yang H.-K.; Zhang X.; Park S.R.; Fujii M.; Kang Y.-K.; Chen L.-T. | The Lancet Oncology | 403 | 263 | |
1997 | Menadione-induced cytotoxicity to rat osteoblasts | JUI-SHENG SUN ; Tsuang Y.-H.; Huang W.-C.; Chen L.-T.; Hang Y.-S.; Lu F.-J. | Cellular and Molecular Life Sciences | 36 | 33 | |
2020 | A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue | Tsai H.-J.; Tai J.J.; Chen L.-T.; MING-SHIANG WU ; KUN-HUEI YEH ; CHUNG-WU LIN ; Wang T.-E.; HSIU-PO WANG ; Yu F.-J.; JYH-MING LIOU ; Hsiao C.-F.; TSU-YAO CHENG ; Yeh H.-J.; Ko C.-W.; Chen M.-J.; Lo G.-H.; Hsu P.-I.; Chang C.-S.; Hwang W.-S.; Chuang S.-S.; Lee H.-W.; CHIA-TUNG SHUN ; Chiu C.-F.; Wang W.-M.; Hsieh C.-Y.; Liu T.-W.; Lin J.-T.; SUNG-HSIN KUO ; ANN-LII CHENG | Haematologica | 5 | 5 | |
2020 | A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma–TCOG T1211 study | Chiang N.-J.; Tsai K.K.; Hsiao C.-F.; SHIH-HUNG YANG ; Hsiao H.-H.; Shen W.-C.; CHIUN HSU ; Lin Y.-L.; Chen J.-S.; Shan Y.-S.; Chen L.-T. | European Journal of Cancer | 9 | 9 | |
2020 | Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study | Chiang N.-J.; Chen M.-H.; SHIH-HUNG YANG ; CHIUN HSU ; Yen C.-J.; Tsou H.-H.; Su Y.-Y.; Chen J.-S.; Shan Y.-S.; Chen L.-T. | Liver International | 6 | 5 | |
2021 | The multiple mediating effects of cancer threat appraisal and quality of life on the association between mindfulness and depression for colorectal cancer survivors | Chen L.-T.; Cheng C.-T.; Huang I.-P.; Chang J.-H.; NIEN-TZU CHANG ; FEI-HSIU HSIAO | Psycho-Oncology | 3 | 3 | |
2016 | Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells | Cho C.-Y.; Huang J.-S.; Shiah S.-G.; Chung S.-Y.; Lay J.-D.; Yang Y.-Y.; Lai G.-M.; ANN-LII CHENG ; Chen L.-T.; Chuang S.-E. | RNA | 33 | 32 | |
2017 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Kang Y.-K.; Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Chen L.-T. | The Lancet | 1656 | 1458 | |
2021 | Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab | Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Nishiyama T.; Chen L.-T.; Kang Y.-K. | Gastric Cancer | 50 | 43 | |
2013 | No evidence of IGH-MALT1-translocation in the Ma-1 cell line-A reply | SUNG-HSIN KUO ; Weng W.-H.; KUN-HUEI YEH ; Chen L.-T.; ANN-LII CHENG | Genes Chromosomes and Cancer | 1 | 1 | |
2019 | Novel insights of lymphomagenesis of helicobacter pylori-dependent gastric mucosa-associated lymphoid tissue lymphoma | SUNG-HSIN KUO ; MING-SHIANG WU ; KUN-HUEI YEH ; CHUNG-WU LIN ; PING-NING HSU ; Chen L.-T.; ANN-LII CHENG | Cancers | 21 | 22 | |
2004 | Nuclear expression of BCL10 or nuclear factor kappa B predicts Helicobacter pylori-independent status of early-stage, high-grade gastric mucosa-associated lymphoid tissue lymphomas | SUNG-HSIN KUO ; Chen L.-T.; KUN-HUEI YEH ; MING-SHIANG WU ; Hsu H.-C.; Yeh P.-Y.; TSUI-LIEN MAO ; Chen C.-L.; SHIN-LIAN DOONG ; Lin J.-T.; ANN-LII CHENG | Journal of Clinical Oncology | 63 | 53 | |
2008 | Overexpression of B cell activating factor of TNF family (BAFF) is associated with Helicobacter pylori independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma | SUNG-HSIN KUO ; Yeh P.-Y.; Chen L.-T.; MING-SHIANG WU ; CHUNG-WU LIN ; KUN-HUEI YEH ; Tzeng Y.-S.; Chen J.-Y.; PING-NING HSU ; Lin J.-T.; ANN-LII CHENG | Blood | 46 | 47 | |
2020 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO | Chen L.-T.; Martinelli E.; ANN-LII CHENG ; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; CHIUN HSU ; YING-CHUN SHEN ; Tabernero J.; Yen Y.; CHIH-HUNG HSU ; Yoshino T.; Douillard J.-Y. | Annals of Oncology | 117 | 112 | |
2019 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS | Muro K.; Van Cutsem E.; Narita Y.; Pentheroudakis G.; Baba E.; Li J.; Ryu M.-H.; Wan Zamaniah W.I.; Yong W.-P.; KUN-HUEI YEH ; Kato K.; Lu Z.; Cho B.C.; Nor I.M.; Ng M.; Chen L.-T.; Nakajima T.E.; Shitara K.; Kawakami H.; Tsushima T.; Yoshino T.; Lordick F.; Martinelli E.; Smyth E.C.; Arnold D.; Minami H.; Tabernero J.; Douillard J.-Y. | Annals of Oncology | 164 | 147 | |
2019 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS | Muro K.; Lordick F.; Tsushima T.; Pentheroudakis G.; Baba E.; Lu Z.; Cho B.C.; Nor I.M.; Ng M.; Chen L.-T.; Kato K.; Li J.; Ryu M.-H.; Wan Zamaniah W.I.; Yong W.-P.; KUN-HUEI YEH ; Nakajima T.E.; Shitara K.; Kawakami H.; Narita Y.; Yoshino T.; Van Cutsem E.; Martinelli E.; Smyth E.C.; Arnold D.; Minami H.; Tabernero J.; Douillard J.-Y. | Annals of Oncology | 104 | 90 | |
2018 | Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: A JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS | Yoshino T.; Arnold D.; Taniguchi H.; Pentheroudakis G.; Yamazaki K.; Xu R.-H.; Kim T.W.; Ismail F.; Tan I.B.; KUN-HUEI YEH ; Grothey A.; Zhang S.; Ahn J.B.; Mastura M.Y.; Chong D.; Chen L.-T.; Kopetz S.; Eguchi-Nakajima T.; Ebi H.; Ohtsu A.; Cervantes A.; Muro K.; Tabernero J.; Minami H.; Ciardiello F.; Douillard J.-Y. | Annals of Oncology | 431 | 383 | |
2015 | Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide | PO-CHIN LIANG ; Ch’ang H.-J.; CHIUN HSU ; Chen L.-T.; TIFFANY TING-FANG SHIH ; Liu T.W. | Hepatology International | 13 | 12 | |
2020 | A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data | Chen L.-T.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Kang Y.-K.; Boku N. | Gastric Cancer | 138 | 130 | |